A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis

Trial Profile

A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Rezafungin (Primary) ; Fluconazole
  • Indications Vulvovaginal candidiasis
  • Focus Therapeutic Use
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 21 Feb 2017 Cidara Therapeutics has discontinued the program for the development of topical CD101 based on unfavourable results of a phase II trial (CT profile 700269339), according to a company media release.
    • 21 Feb 2017 Status changed from recruiting to discontinued, according to a Cidara Therapeutics media release.
    • 20 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top